Theranostics Health Awarded U.S. Patent 9,086,414 for Phospho-erbB2 Diagnostic Marker in Cancer

Theranostics Health Awarded U.S. Patent 9,086,414 Titled: “Phosphorylated c-erbB2 as a Superior Predictive Theranostic Marker for the Diagnosis and Treatment of Cancer”